Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–31 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hemophilia A
Interventions
Colorado Adult Joint Assessment Evaluation
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Orange, California • Aurora, Colorado • Indianapolis, Indiana + 1 more
Conditions
Hemophilia B, Hemophilia A
Interventions
Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Stanford, California + 7 more
Conditions
Hemophilia A, Hemophilia B
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Month and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Duarte, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Conditions
Hemophilia B, Allergic Reactions
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more
Completed Phase 2 Interventional Results available

Efficacy and Safety of IL-11 in DDAVP Unresponsive

NCT00994929
Conditions
Hemophilia A, Von Willebrand Disease
Interventions
Neumega (Oprelvekin, Interleukin 11, IL-11)
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua, Factor IX (FIX)
Genetic · Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Completed Phase 2 Interventional Results available

Dose Confirmation Trial of AAV5-hFIXco-Padua

NCT03489291
Conditions
Hemophilia B
Interventions
AAV5-hFIXco-Padua (AMT-061)
Genetic
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more